PMID- 21562484
OWN - NLM
STAT- MEDLINE
DCOM- 20120508
LR  - 20211020
IS  - 1740-634X (Electronic)
IS  - 0893-133X (Print)
IS  - 0893-133X (Linking)
VI  - 36
IP  - 9
DP  - 2011 Aug
TI  - Blockade of 5-HT2 receptor selectively prevents MDMA-induced verbal memory 
      impairment.
PG  - 1932-9
LID - 10.1038/npp.2011.80 [doi]
AB  - 3,4-Methylenedioxymethamphetamine (MDMA) or 'ecstasy' has been associated with 
      memory deficits during abstinence and intoxication. The human neuropharmacology 
      of MDMA-induced memory impairment is unknown. This study investigated the role of 
      5-HT(2A) and 5-HT(1A) receptors in MDMA-induced memory impairment. Ketanserin is 
      a 5-HT(2A) receptor blocker and pindolol a 5-HT(1A) receptor blocker. It was 
      hypothesized that pretreatment with ketanserin and pindolol would protect against 
      MDMA-induced memory impairment. Subjects (N=17) participated in a double-blind, 
      placebo-controlled, within-subject design involving six experimental conditions 
      consisting of pretreatment (T1) and treatment (T2). T1 preceded T2 by 30 min. 
      T1-T2 combinations were: placebo-placebo, pindolol 20 mg-placebo, ketanserin 
      50 mg-placebo, placebo-MDMA 75 mg, pindolol 20 mg-MDMA 75 mg, and ketanserin 
      50 mg-MDMA 75 mg. Memory function was assessed at Tmax of MDMA by means of a 
      word-learning task (WLT), a spatial memory task and a prospective memory task. 
      MDMA significantly impaired performance in all memory tasks. Pretreatment with a 
      5-HT(2A) receptor blocker selectively interacted with subsequent MDMA treatment 
      and prevented MDMA-induced impairment in the WLT, but not in the spatial and 
      prospective memory task. Pretreatment with a 5-HT(1A) blocker did not affect 
      MDMA-induced memory impairment in any of the tasks. Together, the results 
      demonstrate that MDMA-induced impairment of verbal memory as measured in the WLT 
      is mediated by 5-HT(2A) receptor stimulation.
FAU - van Wel, J H P
AU  - van Wel JH
AD  - Department Neuropsychology and Psychopharmacology, Faculty of Psychology and 
      Neuroscience, Maastricht University, Maastricht, The Netherlands. 
      Janelle.vanWel@maastrichtuniversity.nl
FAU - Kuypers, K P C
AU  - Kuypers KP
FAU - Theunissen, E L
AU  - Theunissen EL
FAU - Bosker, W M
AU  - Bosker WM
FAU - Bakker, K
AU  - Bakker K
FAU - Ramaekers, J G
AU  - Ramaekers JG
LA  - eng
PT  - Controlled Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110511
PL  - England
TA  - Neuropsychopharmacology
JT  - Neuropsychopharmacology : official publication of the American College of 
      Neuropsychopharmacology
JID - 8904907
RN  - 0 (Placebos)
RN  - 0 (Serotonin 5-HT2 Receptor Antagonists)
RN  - 0 (Serotonin Agents)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Adult
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Memory Disorders/*chemically induced/drug therapy/*prevention & control
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*adverse effects/antagonists & inhibitors
MH  - Placebos
MH  - Serotonin 5-HT2 Receptor Antagonists/*pharmacology
MH  - Serotonin Agents/*adverse effects
MH  - Young Adult
PMC - PMC3154112
EDAT- 2011/05/13 06:00
MHDA- 2012/05/09 06:00
PMCR- 2012/08/01
CRDT- 2011/05/13 06:00
PHST- 2011/05/13 06:00 [entrez]
PHST- 2011/05/13 06:00 [pubmed]
PHST- 2012/05/09 06:00 [medline]
PHST- 2012/08/01 00:00 [pmc-release]
AID - npp201180 [pii]
AID - 10.1038/npp.2011.80 [doi]
PST - ppublish
SO  - Neuropsychopharmacology. 2011 Aug;36(9):1932-9. doi: 10.1038/npp.2011.80. Epub 
      2011 May 11.